Sandro Wealth Management LLC Takes Position in Indivior PLC $INDV

Sandro Wealth Management LLC acquired a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 36,585 shares of the company’s stock, valued at approximately $1,313,000.

Other institutional investors have also modified their holdings of the company. CWM LLC bought a new stake in Indivior in the 3rd quarter valued at approximately $25,000. Quarry LP bought a new stake in Indivior in the 3rd quarter valued at approximately $26,000. Raymond James Financial Inc. bought a new stake in Indivior in the 2nd quarter valued at approximately $26,000. Salomon & Ludwin LLC bought a new stake in Indivior in the 4th quarter valued at approximately $30,000. Finally, Harbor Capital Advisors Inc. lifted its stake in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

Insider Activity

In related news, Director Stuart A. Kingsley acquired 940 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were bought at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the purchase, the director directly owned 5,582 shares in the company, valued at approximately $177,842.52. This trade represents a 20.25% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.74% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on INDV. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. HC Wainwright boosted their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Finally, Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Up 2.4%

Shares of Indivior stock opened at $37.66 on Friday. Indivior PLC has a 12-month low of $10.63 and a 12-month high of $40.02. The stock has a market cap of $4.59 billion, a P/E ratio of 22.96 and a beta of 0.90. The business’s 50 day moving average is $31.84 and its 200-day moving average is $32.41.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The company had revenue of $317.00 million for the quarter. On average, sell-side analysts expect that Indivior PLC will post 3 EPS for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.